Tango Therapeutics, Inc. — Form 8-K
Filed October 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Tango Therapeutics announced Phase 1/2 data (cutoff August 20, 2026) for vopimetostat plus daraxonrasib in 22 efficacy-evaluable patients with 2L/3L MTAP-deleted, RAS-mutant pancreatic cancer: 82% objective response rate, median PFS not yet reached, 88% 9-month PFS rate, 100% disease control rate, and generally favorable tolerability (no Grade 4-5 toxicities at dose level 1, 20% dose reduction rate). Tango plans to initiate a global Phase 3 randomized trial in 1H 2027 comparing vopimetostat 200 mg + daraxonrasib 100 mg daily vs. standard-of-care chemotherapy in front-line MTAP-deleted PDAC patients (n=484, dual primary endpoints: ORR and PFS); the company also intends to explore potential 2L approval and expansion into MTAP wild-type tumors.
Why this rating
Phase 3-enabling efficacy data on lead asset in large, underserved market (20k U.S. 1L MTAP-del PDAC annually); ~$528M market cap; Phase 3 initiation 1H 2027 de-risks program but multi-year timeline ahead; requires partner supply (daraxonrasib); $1B cash provides runway but high burn expected.
Price action (we called it positive)
before filing · preread $30.94 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.